鼻咽癌
鼻咽癌
医学
病毒学
肿瘤科
免疫学
内科学
放射治疗
作者
Salvatore Alfieri,Rebecca Romanò,Sara Renata Francesca Marceglia,Carolina Sciortino,W. Ferrari Bravo,Monica Zucchini,Maria Luigia Piscitelli,Imperia Nuzzolese,Stefano Cavalieri,Cristiana Bergamini,Elena Virginia Colombo,Arianna Ottini,Loris De Cecco,Deborah Lenoci,Nicola Alessandro Iacovelli,Marco Guzzo,Ester M. Orlandi,Laura D. Locati,Paolo Bossi,Lisa Francesca Licitra
标识
DOI:10.1016/j.ejca.2025.115625
摘要
BACKGROUND: Plasma Epstein Barr Virus (EBV)-DNA is an established biomarker for endemic EBV-related nasopharyngeal carcinoma (NPC). Its relevance in non-endemic regions is less understood. This study longitudinally assessed plasma EBV-DNA (LEA study) throughout the curative management of non-endemic EBV-related NPC to evaluate its prognostic value. MATERIALS AND METHODS: Between 2012 and 2023, patients with non-endemic, non-metastatic, histologically confirmed EBER+ NPC treated at a tertiary center were retrospectively analyzed. Plasma EBV-DNA levels were measured at pre-treatment (T1), early (T2a, ≤6 weeks) and late (T2b, ≤14 weeks) post-treatment, during follow-up (T3), and after induction chemotherapy (T4), when applicable. EBV-DNA was analyzed for its association with recurrence-free survival (RFS). RESULTS: At a median follow-up of 60 months (range: 9-134), 167 patients were included. Median age was 50 years (range: 22-75), with 72 % male; 84 % had stage III-IV disease (TNM VIII Edition). Pre-treatment EBV-DNA was detected in 96 % of patients, with no predictive cut-off (median RFS: 43 vs. 62 months for detectable vs. undetectable EBV-DNA). Post-treatment undetectable EBV-DNA correlated with better RFS, also with no cut-off. Follow-up EBV-DNA anticipated recurrence in 71 % of cases by a median of 38 days (range: 11-365). Persistently negative follow-up EBV-DNA was observed in 91 % of non-recurrent patients; isolated positive spikes lacked prognostic significance. Post-induction chemotherapy EBV-DNA demonstrated a 92 % negative predictive value for recurrence. CONCLUSIONS: Plasma EBV-DNA is a valuable prognostic biomarker for non-endemic NPC. Pre- and post-treatment undetectable EBV-DNA holds a positive prognostic value. Post-induction EBV-DNA is the most informative timepoint. Longitudinal EBV-DNA monitoring is warranted in clinical practice.
科研通智能强力驱动
Strongly Powered by AbleSci AI